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Summary 
Background: Cancer-associated thrombosis and enduring inflammation are strongly associated 
with cancer progression and metastasis. Heparin, is the mostly clinically used 
anticoagulant/antithrombotic drug, which has recently been shown to exhibit antimetastatic and 
antiinflammatory activities that are linked to inhibition of P- and/or L-selectin. P-selectin-
mediated platelet-tumor cell and tumor-cell endothelium interactions facilitate the initial steps of 
metastasis. Objectives and Methods: The aim of the present study was to determine the capacity 
of dermatan sulfates to inhibit P-selectin and to test their potential to affect thrombosis, 
inflammation and metastasis in respective experimental mouse models. Results: Two dermatan 
sulfates isolated from the ascidians Styela plicata and Phallusia nigra, composed of the same 
disaccharide core structure [IdoA2-GalNAc]n, but sulfated at carbon 4 or 6 of the GalNAc 
residues, respectively, contain opposed HCII activities and are potent inhibitors of P-selectin. 
The ascidian dermatan sulfates effectively attenuated metastasis of both MC-38 colon carcinoma 
and B16-BL6 melanoma cells, and the infiltration of inflammatory cells in a thioglycollate 
peritonitis mouse model. Moreover, both glycosaminoglycans, reduced thrombus size in a FeCl3-
induced arterial thrombosis model, irrespective of their HCII activities. The analysis of arterial 
thrombi demonstrated a markedly reduced platelet deposition after dermatan sulfate treatment, 
suggesting that the glycosaminoglycan inhibited P-selectin and thereby the binding of activated 
platelets during thrombus formation. Conclusions: Collectively, these findings provide evidence 
that specific inhibition of P-selectin represents a potential therapeutic target in thrombosis, 
inflammation and metastasis, and ascidian dermatan sulfates may serve as anti-selectin agents.  
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Introduction 
The relationship between hypercoagulability and cancer was first observed by Trousseau more 
than a century ago [reviewed in 1]. Activation of blood coagulation in cancer patients is a rather 
common complication that has been linked to cancer progression [2]. Tumor cells express tissue 
factor and secrete cytokines that contribute to a prothrombotic microenvironment, which also 
includes activation of platelets. The pathophysiology of thrombosis in cancer is complex, but 
clinical and experimental evidence indicate that platelets represent the link between coagulation 
and cancer progression [3-5]. Activated platelets interact with the activated endothelium and 
contribute to recruitment of leukocytes to inflammatory sites [6]. Platelets are a rich source of 
pro- and anti-angiogenic factors that upon activation may contribute to angiogenesis [7]. 
Furthermore, platelets support the integrity of angiogenic, inflamed [8] and tumor microvessels 
[5]. Experimentally induced thrombocytopenia in tumor bearing animals leads to massive 
hemorrhage at the tumor-stroma interface, indicating a central role of platelets in tumor vascular 
homeostasis [5]. Although thromboembolism and inflammation are linked to cancer in a number 
of different ways, accumulating experimental evidence indicates that P-selectin has an 
integrating role in cancer progression [9-11]. 
P-selectin is a member of the selectin family of cell adhesion molecules that facilitates 
interactions among platelets, leukocytes and endothelial cells [12]. The contribution of selectins 
to physiological processes such as inflammation, reperfusion injury or hemostasis are well 
described [12]. P-selectin is present in the storage granules of endothelial cells (Weibel-Palade 
bodies) and platelets (α-granules), thus enabling rapid cell-surface expression upon activation 
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[12]. Most selectin ligands are based on the terminal tetrasaccharide structure sialyl Lewisx 
(sLex) [12]. During hematogenous metastasis carcinoma cells carrying sLex-containing mucins 
enter the circulation and become potential candidates for selectin-mediated interactions with 
platelets, leukocytes and endothelium [11]. The absence of P- and/or L-selectin leads to 
attenuation of experimental metastasis in different animal models, implicating selectins in cancer 
progression [4, 13, 14]. Formation of platelet-tumor cell emboli is largely mediated by P-selectin 
[4] and contribute to evasion of host responses and to colonization of distant organs [3, 15].  
Accumulating evidence points to the critical role of P-selectin in cancer-associated thrombosis 
[16]. Elevated levels of activated P-selectin-expressing platelets have been observed in advanced 
stages of cancer [17]. Furthermore, the presence of tissue-factor–bearing microparticles 
contributing to the prothrombic state has been observed in the circulation of gastric and 
pancreatic cancer patients [18]. P-selectin signaling through its receptor on leukocytes, P-selectin 
glycoprotein ligand 1 (PSGL-1), induces the generation of tissue factor-positive, highly pro-
coagulant microparticles [10, 19]. Consequently, P-selectin inhibition might have a beneficial 
effect on survival of cancer patients, by attenuating both hematogenous metastasis and 
thromboembolic complications. 
Unfractionated heparin (UFH) and low molecular weight heparins (LMWHs) are commonly 
used for prevention and treatment of cancer-associated thromboembolism [20-22]. Currently 
emerging clinical evidence implicates heparin in prolonging survival of cancer patients [20, 21]. 
There is abundant experimental data indicating that heparins attenuate metastasis by affecting 
angiogenesis, heparanase, P- and L-selectins or binding of cytokines [for review see 23, 24]. 
These observations are further supported by findings that non-anticoagulant heparin derivatives 
also attenuate metastasis [25, 26]. Despite promising results, an effective and safe antithrombotic 
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treatment remains a very challenging clinical task in cancer patients, because of the high risk of 
bleeding complications and thrombotic events in heparin-treated patients [20, 22].  
Previously, we reported the presence of highly sulfated dermatan sulfates (DSs) in solitary 
ascidians (sea squids) from the orders Phlebobranchia (Phallusia nigra) and Stolidobranchia 
(Styela plicata) [27]. These polymers are composed of the same disaccharide backbone, 
consisting of [→4IdoA(2S)β-1→3GalNAcβ-1→], but differ in the position of sulfation on the 
GalNAc, which can be sulfated at carbon 4 or 6 [27]. The DS from the stolidobranchia S.plicata 
is sulfated at carbon 2 of IdoAc and carbon 4 of GalNAc [27] and is a potent activator of heparin 
cofactor II (HCII). In contrast, the DS from the phlebobranchia P.nigra is sulfated at carbon 2 of 
IdoAc and at carbon 6 of GalNAc, and is a poor activator of HCII [27]. 
In the present work, we show that ascidian DSs, but not mammalian DS, attenuate 
hematogeneous metastasis, inflammation-induced leukocytes recruitment and thrombosis. 
Inhibition of P-selectin has been identified as the major biological activity of ascidian DS that 
affects all three processes closely associated with cancer progression.  
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Materials and Methods 
Cell lines and reagents - Human colon carcinoma cells LS180 (ATCC, Manassas, VA) were 
grown in alpha-MEM media (Invitrogen, Carlsbad, CA) supplemented with 10% FCS 
(Invitrogen). Mouse colon carcinoma cell line MC-38, stably expressing GFP MC-38GFP [13] 
and mouse melanoma cell line B16-BL6 [25], were grown in DMEM with 4.5 g/l of glucose 
supplemented with 10% FCS medium (Invitrogen). All reagents were from Sigma (St. Louis, 
MO) unless otherwise stated. Unfractionated heparin – Liquemine (UFH) was obtained from 
Roche Pharma, Switzerland.  
Dermatan sulfates - The ascidian P.nigra was collected in Angra dos Reis, Rio de Janeiro, 
Brazil; S.plicata was collected at Praia da Urca, Rio de Janeiro, Brazil. Dermatan sulfates (DSs), 
were isolated from ascidian visceras by proteolytic digestion followed by anion exchange 
chromatography as described previously [27]. Both ascidian DS contained 2-O sulfation on α-L-
iduronic acid. While S.plicata had additional sulfation in 4-O position of N-acetyl-β-D 
glucosamine unit, P.nigra had sulfated 6-O position. Therefore S.plicata DS was designated as 
2,4-DS while that from P.nigra as 2,6-DS. Mammalian DS was obtained from Sigma Company. 
Oversulfated DS was prepared from a pig mucosal dermatan sulfate [28]. 
Activated partial thromboplastin time assay- aPTT clotting assays were carried out as 
described previously [27]. Briefly, normal human plasma (90 μL) was incubated with 10 μL of 
DS at several dilutions and 100 μL of cephalin. After three minutes at 37oC, 100 μL of 0.25 M 
CaCl2 were added to the mixtures and the clotting time was recorded. The activity is expressed 
as units/mg using a standard unfractionated heparin (200 IU/mg) curve. 
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Inhibition of tumor cell binding to immobilized selectins – The ability of DSs to inhibit the 
adhesion of calcein AM labeled LS180 cells to immobilized P-selectin chimeras was examined 
in a serial dilution of glycosaminoglycans as described previously [25].  
Platelet-tumor cell aggregation in vivo – Lungs were prepared and analyzed at 30 min or 3 h 
after intravenous injection of tumor cells as described previously [4]. Briefly, LS180 cells were 
harvested with 2 mM EDTA in PBS; labeled with Calcein AM and injected intravenously in 
mice with or without previous intravenous application of 100 µg of DSs or 1 mg of UFH (200 
IU/mg) [4]. Lung sections were stained with rat anti-mouse CD41 antibody (Becton Dickinson, 
Mountain View, CA), followed by the goat anti-rat-Alexa 568-conjugated antibody (Invitrogen) 
and analyzed by immunofluorescence microscopy. Calcein-labeled cells present in 40 view fields 
of six different lung sections were scored as “associated” or “not associated” with platelets.  
Experimental metastasis model – Wild type (wt) or P-selectin-deficient mice (P-sel-/-) in 
C57Bl/J6 background (The Jackson Laboratory) were intravenously injected either with 150’000 
B16-BL6 cells or 300’000 MC-38GFP cells via the tail vein. Mice received either PBS or 100 µg 
of mammalian DS, mammalian oversulfated DS, ascidian 2,4- or 2,6-DS intravenously injected 
10 minutes prior to tumor cell injection. Mice injected with melanoma cells were terminated 15 
days later and mice receiving carcinoma cells were terminated after 28 days. PBS-perfused lungs 
were macroscopically evaluated for the presence of metastatic foci. GFP measurement in the 
lungs homogenates from MC-38GFP cells-injected mice were performed as described previously 
[4].  
Thioglycollate-induced peritonitis – Mice were injected with 1 ml of 4% thioglycollate broth 
into the peritoneum. Mice were intravenously injected with PBS, P-selectin function-blocking 
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antibody [29], 2,4-DS or 2,6-DS (4 mg/kg) five minutes after thioglycollate injection. After 4 
hours, mice were terminated and peritoneal cells harvested by injection of 4 ml of PBS 
containing 0.5% BSA and 1 mM EDTA. The total number of cells in peritoneal lavage was 
counted with a hemocytometer. The differential count of polymorphonuclear leukocytes was 
determined in cytospin preparations stained by Hematoxylin and Eosin.  
FeCl3-induced arterial thrombosis – Wt or P-sel-/- C57Bl6 mice were intravenously injected 
with 50 µL of 2,4-DS, 2,6-DS, P-selectin function blocking antibody (4 mg/kg) or PBS, 10 
minutes before induction of thrombosis. Mice were placed in a supine position and the common 
carotid artery (CCA) was exposed. Thrombosis was induced by placing a Whatman filter paper 
saturated with 10% FeCl3 in 10% glycerol on CCA. After three minutes, the FeCl3-paper was 
removed and CCA was rinsed with PBS. Blood flow was monitored with an ultrasonic flow 
probe (Transonic System, USA) until complete vessel occlusion occurred [30]. For histological 
analysis, mice were terminated 20 minutes after removing FeCl3-paper and CCA was carefully 
dissected and frozen in OCT compound (Tissue-Tek, Sakura). Tissue sections were stained with 
hematoxylin and eosin. Platelets were detected with rat anti-mouse CD41 antibody, followed by 
Alexa 568-conjugated goat anti-rat antibody and analyzed by fluorescence microscopy. DAPI 
was used for visualization of cell nuclei. At least five images acquired by Zeiss AM200 microscope were analyzed by Imaris® software per group (Bitplane AG, Zürich, Switzerland). 
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Results 
Dermatan sulfates inhibit tumor cells binding to P-selectin 
To study the structural requirements of ascidian and mammalian dermatan sulfates (DSs) for P-
selectin recognition, we tested the capacity of DSs to inhibit binding of LS180 cells to P-selectin. 
(Figure 1A). Ascidian DSs (2,4-DS or 2,6-DS) as well as a chemically oversulfated mammalian 
DS (OSDS) inhibited tumor cell binding to P-selectin at comparable levels, with an IC50 of 13.5 
µg/ml (ascidian 2,4-DS) and 12.2 µg/ml (ascidian 2,6-DS) and 12.6 µg/ml (OSDS). All 
disulfated DSs were superior to UFH (24.5 µg/ml). In contrast, single sulfated mammalian 4-DS 
from porcine skin did not inhibit P-selectin binding to tumor cells even at higher concentrations. 
These observations indicate that the sulfation degree of dermatan sulfate is critical for P-selectin 
recognition (Table 1). While ascidian DSs contain high levels of 2,4- or 2,6-disulfated 
disaccharides, 66% and 78%, respectively [27], mammalian DS contains mostly 4-monosulfated 
disaccharide units (80%). Disaccharide analysis of OSDS from porcine skin revealed a distinct 
sulfation pattern composed of mostly 4,6- disulfated disaccharides (35.5%) and containing small 
amount of 2,6-disulfated, 6-monosulfated and trisulfated disaccharides, 18.3%, 20.4% and 23.4% 
respectively. OSDS or ascidian DSs showed similar IC50 values in the P-selectin binding assays, 
suggesting that degree of sulfation, rather than the position of sulfate groups, is critical for P-
selectin interaction. In contrast, the anticoagulant activity of ascidian DSs has been shown to 
depend on the position of sulfation on the N-acetylgalactosamine [27].  
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L-selectin also binds GAGs such as heparin and heparan sulfate [31]. Although, L-selectin 
binding to 2,4 and 2,6-DSs was less efficient than of P-selectin (2-fold lower), it was comparable 
to the binding of unfractionated heparin (Suppl. Figure 1).  
P-selectin-mediated binding of platelets to selectin ligands on tumor cells significantly 
contributes to tumor cell emboli formation [4]. To test ascidian DSs as inhibitors of P-selectin-
mediated interactions in vivo, mice were injected with calcein-labeled LS180 cells 10 minutes 
after application of DSs (100 µg/mouse), PBS, or UFH (1 mg/mouse). The extent of platelet-
tumor cell emboli in the lung microvasculature was evaluated 30 min and 3 hours later (Figure 
1B). Initial seeding of tumor cells in lungs was comparable among all groups after 30 min but the 
number of viable tumor cells detected after 3 h significantly decreased in mice injected either 
with DSs or heparin. These results confirmed that ascidian DSs are potent inhibitors of P-
selectin-mediated interactions also in vivo, while the inhibitory effect of DSs lasted for at least 3 
hours.  
 
Ascidian DSs attenuate experimental metastasis 
Inhibition of P-selectin or the absence of P-selectin has been previously shown to attenuate 
metastasis [4, 14]. To determine the ability of ascidian DSs to attenuate metastasis, wt mice were 
intravenously injected with 100 µg of each ascidian DS followed by injection of MC-38GFP 
cells. After twenty eight days, mice were terminated and lungs evaluated for metastasis (Figure 
2). Both ascidian DSs (2,4-DS or 2,6-DS) markedly attenuated metastasis, when compared to 
PBS injected control mice with lungs displaced by metastasis (Figure 2A). Lungs of ascidian 
DSs-treated mice showed only a few metastatic foci, 0-7 foci per lung (Figure 2B). Injection of 
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mammalian DS did not affect metastasis, which is in agreement with the previous observation 
that 4-DS had no effect on P-selectin inhibition (Figure 1A). To confirm that the antimetastatic 
effect of DS is dependent on P-selectin, we intravenously injected ascidian DSs followed by 
MC-38GFP in P-selectin-deficient mice (P-sel-/-) (Figure 2B). While P-selectin deficiency alone 
markedly reduced metastasis [4, 13], small number of metastatic foci were clearly detectable (3-
25 foci per lung). However, 2,4- or 2,6-DS had only minimal additional effect on metastasis, 
indicating that the anti-metastatic effect of ascidian DSs in wt mice depends on inhibition of P-
selectin-mediated interactions. 
The anti-metastatic effect of ascidian DSs was also evaluated with B16-BL6 melanoma cells, 
which were previously reported to express P-selectin ligands, albeit to a lesser extent than MC-
38 cells [25]. Both ascidians DSs attenuated metastasis of B16-BL6, although less efficiently 
than by MC-38GFP cells (Figure 3). 
 
Ascidian DSs inhibit recruitment of polymorphonuclear cells 
There is accumulating evidence that inflammatory cells affect tumorigenesis and metastasis, 
although the underlying mechanism is still under investigation [32, 33]. Since ascidian DSs are 
potent P-selectin inhibitors, we tested their capacity to inhibit leukocyte recruitment in a 
thioglycollate-induced peritonitis mouse model. Intraperitoneal injection of 4% thioglycollate 
was followed by intravenous injection of 100 µg of 2,4- or 2,6-DS or P-selectin function-
blocking antibody (P-sel Ab), respectively. Analysis of peritoneal lavage leukocytes showed a 
three-fold increase in the number of polymorphonuclear cells (PMN) in thioglycollate treated 
mice when compared to controls (Figure 4A). Both ascidian DSs significantly reduced leukocyte 
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recruitment, primarily PMNs (Figure 4B). Ascidian DSs reduced peritoneal recruitment of PMNs 
to the similar extent as observed in mice treated with P-sel Ab. Thus, inhibition of P-selectin and 
possibly L-selectin are primarily responsible for the anti-inflammatory effect of ascidian DSs. 
 
Ascidian DSs inhibit arterial thrombosis 
To test whether P-selectin inhibition by DSs affects thrombosis, we applied ascidian DSs in the 
FeCl3-induced carotid artery lesion model. An increased time to occlusion has been observed for 
both anticoagulant dermatans, 2,4-DS and mammalian DS respectively (Figure 5A). Although 
2,6-DS has low HCII-mediated anticoagulant activity [27], it was able to trigger a small but 
significant prolongation of the occlusion time. Furthermore, we observed similar prolongation of 
the occlusion time both in P-sel-/- mice and wt mice treated with P-sel Ab (Figure 5A). 
Representative normalized blood flow curves obtained from experiments with mice treated either 
with 2,6-DS or P-sel Ab revealed a tendency to an increase of the initial plateau, followed by a 
sharp drop in the blood flow (Figure 5B). Interestingly, the curve obtained in the experiments 
with 2,4-DS-treated mice showed not only the same prolonged initial plateau, but also a milder 
drop (green line). To test whether P-selectin inhibition by DSs affects thrombus formation, we 
analyzed the carotid arteries 20 min after the induction of thrombosis. Histological analysis 
revealed smaller thrombi in mice treated with 2,4- and 2,6 DS, but a marked difference in 
thrombi composition was observed (Figure 5C). Whereas control mice and mammalian DS-
treated mice showed massive thrombi, mice treated with ascidian DSs or P-sel-Ab showed less 
compact thrombi. Further analysis of platelet content revealed platelet-poor thrombi in mice 
treated either by P-sel Ab or ascidian DSs, while platelet content in mammalian DS-treated mice 
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was only partially reduced (Figure 5C). These observations provide evidence that inhibition of P-
selectin by ascidian DS attenuates thrombi formation by inhibition of platelet deposition.  
 
 
Discussion 
Cancer patients are at high risk for venous thromboembolism (VTE) and P-selectin was recently 
identified as an independent risk factor [16, 34]. The capacity of tumor cells to activate the 
hemostatic system appears to be critical not only for thrombotic events but also favors tumor 
progression, angiogenesis, and metastasis [2, 20]. P-selectin binding to PSGL-1 that is mainly 
present on leukocytes triggers, together with other mediators, the release of procoagulant 
microparticles from leukocytes and platelets [10]. The number of microparticles is elevated in 
patients with deep venous thromboembolism [35] and also in experimental mouse model of 
venous thrombosis [19, 36]. Here we provide evidence that inhibition of P-selectin by ascidian 
DS affects thrombosis (Figure 5). The anticoagulant activity of DSs is given by the enhancement 
of the catalytic activity of Heparin Cofactor II (HCII), a serine protease inhibitor (SERPIN) 
present in the plasma, which inhibits thrombin directly and selectively and reduces thrombin 
generation [37]. The presence of (IdoA2S-GalNAc,4S) units is essential to the anticoagulant 
activity of DS polymers. Accordingly, 2,6-DS presents no appreciable anticoagulant activity 
while 2,4-DS is highly anticoagulant (Table 1) [27]. This difference in the anticoagulant activity 
of ascidian DSs was confirmed by aPTT ex vivo and a stasis/hypercoagulability-induced model 
of venous thrombosis [38]. The 2,4-DS decreased the thrombus weight by 90% while the 2,6-DS 
did not have any significant effect. Further analysis on an arterial endothelial photochemical 
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injury model indicated that 2,4-DS as well as mammalian DS (4-DS) significantly prolonged the 
occlusion time in wild type mice. Interestingly, 2,6-DS treatment resulted in a visible tendency to 
prolong the occlusion time, despite its low HCII activity [37]. Moreover both ascidian DSs and 
not porcine DS, had a low but significant antithrombotic activity in HCII-/- mice. The aPTT 
performed with plasma from HCII-/- mice did not show any variation after treatment with 
mammalian or 2,6-DS and only a slight prolongation after 2,4-DS. Altogether, the antithrombotic 
activity of ascidians DSs may involve HCII-dependent and HCII-independent mechanisms [37]. 
Although the HCII-independent antithrombotic effect of ascidian DSs remains to be fully 
determined, the presented evidence (Figure 5) suggests that 2,6-DS inhibits P-selectin and 
thereby platelet accumulation, which reduces thrombi formation. Previously, prolonged time to 
occlusion was observed in P-selectin deficient mice using the FeCl3-induced arterial thrombosis 
model [39]. Thrombi formed in the carotid artery of wt mice showed a higher content of 
leukocytes in comparison to P-sel-/- mice. Inhibition of P-selectin by function-blocking antibody 
decreased leukocyte accumulation and deposition of fibrin into growing thrombi in an 
arteriovenous shunt model in baboons [40]. Although we did not analyze the leukocyte content 
of thrombi, the inhibition of the P-selectin-dependent formation of large aggregates containing 
platelets and leukocytes might be an important mechanism for the antithrombotic effect of 
ascidian DSs. 
Cancer patients are in a pro-thrombotic state and soluble P-selectin (sP-selectin) has been 
suggested to be a relevant marker of cancer-related thrombosis that strongly correlates with 
mortality [34]. The binding of sP-selectin to its main ligand expressed on the leukocyte surface 
(PSGL-1) leads to leukocyte activation, resulting in a release of tissue factor-bearing 
microparticles from leukocytes [41]. Such microparticles have been shown to accumulate in the 
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developing thrombi in a P-selectin- and PSGL-1-dependent manner [42]. Although we have 
shown that inhibition of platelet P-selectin affects thrombi formation, the subsequent production 
of microparticles by leukocytes, as well as their deposition in the forming thrombus may also be 
hampered by treatment with ascidian DSs.  
P-selectin expressed on activated endothelium and/or platelets, has been shown to be essential 
for inflammatory leukocyte recruitment allowing cell tethering and rolling on activated 
endothelium [43]. The results obtained from the thioglycollate-induced peritonitis model showed 
that ascidian DS was as potent as the inhibition of P-selectin by function-blocking Ab or the 
absence of P-selectin in inhibition of PMN recruitment (Figure 4). Since ascidian DSs also 
efficiently bind to L-selectin (Suppl Figure 1), direct inhibition of leukocyte recruitment through 
L-selectin can be expected. In addition to selectin inhibition, ascidian-derived 
glycosaminoglycans (including DSs) have the potential to bind cytokines and growth factors and 
thereby interfere in cytokine-mediated inflammatory responses or growth factor mediated tumor 
progression [44]. Whether ascidian DSs contribute to a reduced leukocyte recruitment or 
attenuation of metastasis by displacing cytokines and/or growth factors remains to be 
determined.  
There is accumulating evidence that P-selectin with its activity ranging from a cell-adhesion 
molecule to a signaling mediator [45], might be a valuable pharmacological target in cancer [4, 
46], inflammation [47] and thrombosis [19]. In comparison to clinically used heparins, ascidian 
DS are rather abundant biological compounds. Further characterization of ascidian DS is 
certainly necessary, but their potential to affect thrombosis, inflammation and metastasis by 
specifically targeting P-selectin-mediated interactions makes them a potential agents for further 
therapy development.  
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Figure Legends 
Figure 1. Inhibition of LS180 cell binding to P-selectin in vitro and platelets in vivo A) 
Adhesion of LS180 cells to immobilized P-selectin chimera was measured in the presence of 
increasing concentrations of porcine DS (squares), chemically oversulfated DS (triangles) or 
ascidians, 2,4-DS (opened squares) or 2,6-DS (diamonds), respectively. Unfractionated heparin 
(UFH) was used as positive control (circle). Each curve is representative of three independent 
experiments. B) Number of tumor cells detected in the lungs at 30 min and 3 h after injection 
was analyzed in the presence/absence of ascidian DSs (100 µg), UFH (200 IU) or PBS, 
respectively. Platelet adhesion to intravenously injected tumor cells. The number of platelet-
tumor cell aggregates is presented in percentage (in columns) of all counted tumor cells. The 
statistical significance of tumor-cell-platelet aggregation was determined by ANOVA analysis of 
variance; *** p<0.001. 
 
Figure 2. Ascidian DSs attenuate experimental metastasis of MC-38GFP carcinoma cells. 
Wt mice or P-sel-/- were intravenously injected with ascidians DSs (100 µg) followed by i.v. 
injection of MC-38GFP cells (300’000) 10 minutes later. Metastasis was evaluated after 28 days. 
A) Representative examples of dissected lungs from wt mice are shown. B) Metastatic foci 
counts. C) Total tumor burden was quantified by GFP fluorescence measurement in the lung 
homogenate. The statistical significance was determined by ANOVA analysis of variance; ** 
P<0.01; *** p<0.001. 
 
Figure 3. Ascidian DSs attenuate experimental metastasis of B16-BL6 melanoma cells. Wt 
mice were intravenously injected with ascidians DSs (100 µg), followed by injection of B16-
BL6 cells (150’000) 10 minutes later. Mice were terminated after 14 days and lungs were 
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macroscopically evaluated. A) Representative images of lungs injected with PBS or ascidian 
DSs. B) Quantification of metastatic foci in lungs are shown. The statistical significance was 
determined by ANOVA analysis of variance; ** P<0.01.  
 
Figure 4. PMN recruitment in a thioglycollate-induced peritoneal inflammation model is 
inhibited by ascidian DSs. Mice were injected intraperitoneally with 4 % thioglycollate broth 5 
minutes before intravenous injection of PBS, P-sel-Ab, 2,4-DS or 2,6-DS (100 µg/mouse), 
respectively. After 4 h the peritoneal lavage was evaluated for the total amount of cells (B) and 
the percentage of PMN cells (C). PMN were identified by H&E staining of lavage cells (A). The 
statistical significance was determined by one-way ANOVA analysis; *** P<0.001. Bar = 20 
µm.  
 
Figure 5. Ascidian DSs reduces FeCl3-induced arterial thrombosis primarily by P-selectin. 
Mice were intravenously injected with PBS, P-sel-mAb, porcine DS, 2,4-DS or 2,6-DS (100 
µg/mouse), respectively, and 10 minutes later thrombus formation was induced by placing a 
filter paper soaked with 10% FeCl3 on the common carotid artery (CCA). Flow was monitored 
with an ultrasonic flow probe until occlusion of CCA. A) Time to occlusion measurement in wt 
and P-selectin deficient mice upon treatments as shown. B) Representative flow curves of 
normalized blood flow registered during the experiment. C) After 20 minutes of thrombosis 
induction, CCAs were harvested and frozen. Representative images of arterial sections stained 
with hematoxylin & eosin (H&E) and platelet staining with anti-CD41 antibody (red) are shown. 
Bar H&E = 50 µm, Bar CD41 = 20 µm. D) Platelet content was quantified by Imaris software as 
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described in ‘Material and Methods’. The statistical significance was determined by one-way 
ANOVA analysis (*P<0.05; ** P<0.01; *** p<0.001). 
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Table 1.  
Disaccharide content, anticoagulant and P-selectin inhibitory activities of DSs 
Dermatan sulfate Major disaccharide unit (%) aPTT (IU/mg)
c 
Inhibition of tumor 
cell adhesion to    
P-selectin  
IC 50 (µg/ml) 
Porcine DS 
α-∆HexUA-GalNAc(4S)a  
(80 %) 2a - 
2,4-DS 
 
α-∆HexUA(2S)-GalNAc(4S)a 
(66 %) 8a 13.51 
2,6-DS 
 
α-∆HexUA(2S)-GalNAc(6S)a 
(75 %) 0.4a 12.19 
OSDSd 
 
α-∆HexUA-GalNAc(4S,6S)b 
(36 %) 11.5 12.56 
a Data from Pavão MS et al (27)   
  b Obtained by disaccharide analysis 
 c The anticoagulant activity of heparin and its derivatives was determined in human plasma 
samples as described (27). 
d OSDS = oversulfated mammalian dermatan sulfate. 
 
 





